A SBIR funding freeze is severely impacting life sciences startups, robotics innovators, and deep-tech ventures following the expiration of the Small Business Innovation Research program three months ago, forcing many Maryland firms and thousands of small businesses to slash research budgets, delay FDA trials, and eye Chinese investors for survival capital.

Congress allowed the SBIR and Small Business Technology Transfer (STTR) programs, which provide $4 billion annually and have been responsible for over 800 IPOs and 2,000 acquisitions, to expire on September 30, 2025, due to Senate gridlock.

Consequently, agencies like the National Institute of Health (NIH) halted new awards, NASA froze solicitations, and DoD suspended $1.6 billion in warfighter technology contracts, leaving 10,000 small businesses in limbo.

Senator Joni Ernst blocked a straightforward one-year SBIR funding extension and demanded controversial reforms instead. This led to the NIH’s early announcement of funding opportunity expirations, effectively cutting off the primary source of non-dilutive capital for deep-tech startups.

“It’s clear SBIR is in need of additional reforms to safeguard taxpayer funds and enable this program to meet its full potential,” Ernst said during committee hearings, pushing her INNOVATE Act to overhaul program rules.

Political shifts may occur, with potential reauthorization through February 2026 appropriations bills. However, the three-month funding gap has already cost startups about $880 million in halted R&D funding.

Life Sciences Sector Faces Brutal Squeeze

The life sciences sector is feeling the brunt of this freeze. NIH SBIR approval rates plummeted in 2024, with Phase I approvals falling to 9.9 percent and Phase II to 18 percent. Moreover, Phase I awards collapsed from 671 in 2019 to just 369 in 2024, creating a brutal bottleneck for life sciences startups competing for shrinking funding pools.

Maryland firms received $139.4 million in SBIR awards in 2024, but now companies like Linshom Medical and Irazu Oncology are struggling. Linshom, with three FDA clearances, is having trouble securing funding for clinical trials. Irazu, founded in 2022, has had multiple grant applications rejected.

Jeff Strovel, Irazu’s CEO said, “A lot of companies are just going to go bankrupt and shut down.” He admits the startup now courts Chinese venture firms and pharmaceutical giants, exactly the outcome national security experts fear.

“It’s not ideal, but you have to keep the company open,” Strovel added.

With domestic capital tight, some firms are turning to Chinese investors, risking the offshoring of vital US biotech research.

Robotics companies are also affected, as developing prototypes requires substantial funding. The NSF has historically provided non-dilutive capital, but that capital is now in jeopardy. For example, Pike Robotics recently secured $1.2 million in funding but now faces uncertainty.

Life sciences startups are under increased pressure, with venture capital remaining low and higher proof-of-concept expectations. The average cost to bring a new drug to market exceeds $700 million, making SBIR funding essential before companies attract further investment.

Broader Economic Implications

The SBIR funding freeze ripples extend far beyond individual companies. Research shows that SBIR programs generate substantial economic returns: 25 percent of top NIH Phase II winners have historically attracted venture capital investment, and the program as a whole has created multiplier effects reaching 6x in specific technology sectors.

Maryland firms, in particular, feel the squeeze because the state has built an entire ecosystem to support SBIR success. Montgomery County offers matching grants up to $100,000 for Phase I and $250,000 for Phase II, but these state programs require active federal SBIR awards to trigger, making them useless during the freeze.

Meanwhile, life sciences startups face compounding pressures. Biotech venture capital remains depressed following post-pandemic corrections, with investors demanding higher proof-of-concept bars. The median cost to bring new drugs to market reaches $708 million; SBIR provides critical early funding before companies achieve VC-attractive milestones.

Without SBIR, companies get trapped in an expanded “valley of death”—unable to complete preclinical studies that would unlock Series A funding, yet lacking resources to bootstrap through expensive regulatory pathways.

DoD Technology Pipeline at Risk

The Department of Defense’s (DoD) freeze on $1.6 billion in small-business contracts also affects critical technologies, including missile-tracking algorithms and battlefield robotics. The implications extend beyond individual businesses.

Defense Department stakeholders express alarm over national security implications. DoD distributed over $1.6 billion annually through SBIR/STTR to 10,000+ small business contractors developing dual-use technologies. These contracts fund critical capabilities that large defense primes cannot efficiently develop.

The Space Development Agency’s Enhanced Orbital Vision (EO Vista) program, for example, relies heavily on SBIR-funded small businesses for satellite-tracking technologies and hypersonic threat-detection systems. The freeze potentially delays warfighter technology deployment timelines by 6-12 months, analysts warn.

Survival Strategies for Stranded Startups

Operators desperately pivot to alternative funding sources. Maryland firms tap state matching programs, though these require active federal awards. Deep-tech ventures court strategic corporate partnerships, accepting terms that are tougher than the typical SBIR zero-equity structure.

Some life sciences startups explore foreign capital, particularly from Chinese pharmaceutical companies and venture firms actively recruiting US biotech talent. This trend alarms policymakers concerned about intellectual property migration and the erosion of national competitiveness.

BioHealth Innovation in Baltimore advises companies to build 6-12 month cash reserves and prepare for potential “catch-up” solicitations when reauthorization eventually occurs. Investors increasingly prioritize companies with proven SBIR track records, viewing past awards as validation signals amid uncertainty.

Reauthorization Timeline Remains Murky

As of January 2026, congressional sources indicate reauthorization may occur through February appropriations legislation or be bundled into larger fiscal packages. However, Senator Ernst’s reform demands create ongoing political obstacles to clean extensions.

The House passed H.R. 5100, a straightforward one-year extension, in September 2025 with bipartisan support. Yet Senate procedures allow individual senators to block unanimous consent, giving Ernst leverage to demand programmatic changes opposed by Democrats and small-business advocacy groups.

Ultimately, this SBIR funding freeze tests the resilience of America’s innovation ecosystem like no prior policy shock. Founders who diversify funding sources endure; those dependent solely on SBIR face potential extinction. The coming weeks will determine whether thousands of life sciences startups, robotics firms, and deep-tech ventures survive to commercialize breakthrough technologies, or whether critical intellectual property migrates overseas to better-capitalized competitors.

Follow USTechTimes on Facebook, Twitter and Linkedin for in-depth news of market trends, funding updates, and regulatory changes affecting startups in USA.

We Recommend: